Brothers faced setback when a Singapore arbitration court imposed a $390 million fine on them for allegedly suppressing and misrepresenting facts when they sold their pharma firm, Ranbaxy Laboratories, to Japan's Daiichi Sankyo 8 years ago. The Singhs denied any wrongdoing and are contesting the ruling in both Singapore and India. Their hospital chain, Fortis Healthcare, which Malvinder runs as executive chairman, is demerging its diagnostics business. The brothers rejoined the board of financial firm Religare Enterprises in a nonexecutive capacity in July after a 6-year gap. Shivinder retired from business last year to work for a spiritual organization.